120739-94-8

Basic information

• Product Name: METHYL-THIAZOL-4-YLMETHYL-AMINE
• Synonyms: METHYL-THIAZOL-4-YLMETHYL-AMINE;N-Methyl-1-(thiazol-4-yl)MethanaMine;N-methyl-1-(1,3-thiazol-4-yl)methanamine
• CAS NO: 120739-94-8
• Molecular Formula: C5H8N2S
• Molecular Weight: 128.2
• EINECS: 604-604-1
• Mol File: 120739-94-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 199.0±15.0 °C(Predicted)
• Appearance: /
• Density: 1.126±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.07±0.10(Predicted)
• CAS DataBase Reference: METHYL-THIAZOL-4-YLMETHYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL-THIAZOL-4-YLMETHYL-AMINE(120739-94-8)
• EPA Substance Registry System: METHYL-THIAZOL-4-YLMETHYL-AMINE(120739-94-8)

Safety Data

• Hazardous Substances Data: 120739-94-8(Hazardous Substances Data)

Usage

General Description

Methyl-thiazol-4-ylmethyl-amine is an organic compound with the chemical formula C5H7N3S. It belongs to the thiazole family and contains a methyl group attached to a thiazole ring. METHYL-THIAZOL-4-YLMETHYL-AMINE is commonly used in the pharmaceutical industry and as a building block in the synthesis of various chemical compounds. Methyl-thiazol-4-ylmethyl-amine has been studied for its potential application in the treatment of certain neurological and psychiatric disorders due to its interaction with specific neurotransmitter receptors in the brain. It is important to handle this chemical with caution due to its potential to cause skin and eye irritation.

Upstream product

• 7709-58-2 4-(chloromethyl)thiazole hydrochloride 
• 74-89-5 methylamine 
• 3364-76-9 4-chloromethylthiazole 
• 52829-53-5 4-bromomethyl-1,3-thiazole 
• 115-08-2 thiocarboxamide 
• 534-07-6 1,3-Dichloroacetone 

Downstream Products

• 1350623-21-0 4-[(methylamino)methyl]-1,3-thiazole-2-carbaldehyde (6-cyclohexylthieno[2,3-d]pyrimidin-4-yl)hydrazone 
• 1562429-43-9 C₃₄H₄₂N₆O₄S₂ 
• 144186-01-6 {4-[3-((S)-1-{(1S,3S,4S)-1-Benzyl-2,3-dihydroxy-4-[(S)-3-methyl-2-(3-methyl-3-thiazol-4-ylmethyl-ureido)-butyrylamino]-5-phenyl-pentylcarbamoyl}-2-methyl-propyl)-1-methyl-ureidomethyl]-thiazol-2-yl}-carbamic acid tert-butyl ester 
• 144163-73-5 (S)-3-Methyl-2-(3-methyl-3-thiazol-4-ylmethyl-ureido)-butyric acid 4-nitro-phenyl ester 

Relevant articles and documents

Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)

The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of cytochrome P450 3A (CYP3A). However the potent anti-HIV activity of ritonavir may limit its use as a pharmacoenhancer with other classes of anti-HIV agents. Ritonavir is also associated with limitations such as poor physicochemical properties. To address these issues a series of compounds with replacements at the P2 and/or P3 region was designed and evaluated as novel CYP3A inhibitors. Through these efforts, a potent and selective inhibitor of CYP3A, GS-9350 (cobicistat) with improved physiochemical properties was discovered.

MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS

The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.